| Q54112410 | A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib. |
| Q51441965 | B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. |
| Q38659428 | B-cell receptor pathway modulators in NHL. |
| Q58088141 | Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies |
| Q36278006 | Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes |
| Q30383411 | CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. |
| Q40144297 | Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. |
| Q39325783 | Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies |
| Q60019713 | Current challenges in the management of follicular lymphoma |
| Q39044162 | Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now? |
| Q49279565 | Current trials for frontline therapy of mantle cell lymphoma |
| Q90183400 | Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma |
| Q90450484 | Disparities in survival by insurance status in follicular lymphoma |
| Q42503470 | Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling |
| Q38720593 | Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options |
| Q38817591 | From identification of the BTK kinase to effective management of leukemia. |
| Q42091318 | Ibrutinib and rituximab induced rapid response in refractory Richter syndrome |
| Q38694168 | Ibrutinib for mantle cell lymphoma |
| Q26783430 | Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion |
| Q49817207 | Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma |
| Q52681376 | Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. |
| Q42368314 | Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach |
| Q101121282 | Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances |
| Q38939419 | Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done? |
| Q36437030 | Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. |
| Q91599180 | Mantle Cell Lymphoma: An Evolving Therapeutic Landscape |
| Q38480491 | Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation |
| Q61805953 | Mantle cell lymphoma and its management: where are we now? |
| Q28075606 | Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents |
| Q40680175 | Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma |
| Q89933141 | Non-Hodgkin lymphoma |
| Q28076335 | Novel Drugs in Follicular Lymphoma |
| Q26782270 | Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy |
| Q38787781 | Novel agents in follicular lymphoma: choosing the best target. |
| Q39290199 | Novel agents in mantle cell lymphoma |
| Q38818380 | Obinutuzumab for the treatment of indolent lymphoma |
| Q55281964 | Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies. |
| Q38612385 | Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies |
| Q90424234 | PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR |
| Q55610546 | Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. |
| Q38544216 | Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly |
| Q53630006 | Rehabilitation or the death penalty: autoimmune B cells in the dock. |
| Q33877999 | Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose |
| Q54214982 | Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. |
| Q26795594 | Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms |
| Q38691282 | Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. |
| Q58613953 | Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies |
| Q38351184 | Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies |
| Q38917848 | Targeting indolent non-Hodgkin lymphoma |
| Q27025812 | Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib |
| Q38744922 | Targeting of B-cell receptor signalling in B-cell malignancies. |
| Q38791124 | Targeting protein kinase C in mantle cell lymphoma |
| Q38947107 | The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma |
| Q58615642 | The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies |
| Q64121132 | Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead |
| Q48546805 | VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study |
| Q39027817 | Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. |
| Q86848622 | [Progress of bendamustine in the treatment of B cell non-Hodgkin lymphoma] |